MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "COMT inhibitors"

  • 2025 International Congress

    Risk of Motor Complications in Early Parkinson’s Disease Patients Treated with Opicapone in the EPSILON study: Effect of Levodopa Dose

    J. Ferreira, O. Rascol, F. Stocchi, A. Antonini, H. Brigas, J. Moreira, JF. Rocha, M. Fonseca, D. Ramos, J. Holenz, W. Poewe (Lisbon, Portugal)

    Objective: This post-hoc analysis of the EPSILON study evaluated whether levodopa dose (<400mg/day vs. ≥400mg/day) and opicapone (OPC) timing (at double-blind [DB] or open-label extension…
  • 2025 International Congress

    Effect of Opicapone on Sleep-Related Complaints and Non-Motor Burden in Parkinson’s Patients: A Post-Hoc Analysis of the OASIS Trial

    J. Ferreira, M. Gago, R. Costa, M. Fonseca, H. Brigas, D. Martins, J. Holenz, C. Trenkwalder (Lisbon, Portugal)

    Objective: To assess the effect of opicapone (OPC) on different sleep complaints and non-motor symptoms (NMS) in fluctuating Parkinson’s disease (PD) patients with sleep disturbances.…
  • 2025 International Congress

    Comparative efficacy of opicapone and entacapone in the management of motor fluctuations in Parkinson’s disease

    S. Isaacson, F. Amjad, S. Thakkar, D. Martins, H. Brigas, G. Banisadr, S. Fisher (Boca Raton, USA)

    Objective: To compare the clinical efficacy of two catechol-O-methyltransferase (COMT) inhibitors, opicapone (OPC) and entacapone (ENT). Background: OPC and ENT are used as adjunctive therapy…
  • 2025 International Congress

    Long-Term Effect of Opicapone in Parkinson’s Patients Without Motor Complications: 1.5-year EPSILON Study Findings

    J. Ferreira, O. Rascol, F. Stocchi, A. Antonini, H. Brigas, J. Moreira, JF. Rocha, M. Fonseca, J. Holenz, W. Poewe (Lisbon, Portugal)

    Objective: We report motor function, motor complication and tolerability findings of the EPSILON study up to 1.5 years. Background: The 24-week, double-blind, placebo-controlled Phase III…
  • 2025 International Congress

    Effectiveness of Opicapone Added to Different Levodopa Doses and LEDDs in Parkinson’s Disease: Post-Hoc Analysis of the ADOPTION Trials

    J. Ferreira, JY. Lee, HI. Ma, B. Jeon, W. Poewe, A. Antonini, F. Stocchi, D. Rodrigues, M. Fonseca, H. Brigas, J. Holenz, O. Rascol (Lisbon, Portugal)

    Objective: To assess the efficacy of opicapone 50 mg, compared to an additional 100 mg dose of levodopa, in reducing OFF-time in Parkinson’s disease (PD)…
  • 2025 International Congress

    Opicapone for OFF Motor Fluctuations in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Trials

    A. Fornari Caprara, J. Pitton Rissardo (Camden, USA)

    Objective: To evaluate the efficacy of opicapone 50 mg in reducing OFF time and improving motor function in Parkinson’s disease (PD) patients with motor fluctuations.…
  • 2025 International Congress

    Early Introduction of COMT Inhibitors at Low Levodopa Doses Improves Long-Term Motor Complications in Parkinson’s Disease: A sub-analysis of the REONPARK Study

    J. García-Caldentey, D. Vilas Roldán, L. López-Manzanares, H. Brigas, D. Martins, J. Reis, J. Blanco Ameijeiras, M. Rodríguez-de Miguel, I. Tegel Ayuela (Palma de Mallorca, Spain)

    Objective: This sub-analysis of the REONPARK study aims to identify predictive factors for the greater effectiveness of COMT inhibitors (COMTi) in alleviating motor complications in…
  • 2025 International Congress

    Safety Profile of Opicapone in Elderly and Very Elderly Population

    D. Lopes, I. Peixoto, D. Martins, H. Brigas, H. Gama, J. Holenz (Coronado, Portugal)

    Objective: This study aimed to characterize the safety profile of opicapone (OPC) in the elderly and compare post-marketing safety between (A) very elderly patients (≥…
  • 2025 International Congress

    COMT-Inhibitors Clinical Experience In Early Motor Fluctuations. Three Months Analysis Of REONPARK Study

    L. López-Manzanares, M. Cerdán Sánchez, T. Delgado Ballestero, B. Solano Vila, J. García-Caldentey, A. Rodríguez-Sanz, H. Brigas, D. Martins, J. Blanco Ameijeiras, M. Rodríguez-de Miguel (Madrid, Spain)

    Objective: The REONPARK study aims to evaluate COMT inhibitors (COMTi) effectiveness and tolerability in alleviating motor complications associated with L-dopa treatment in Parkinson’s disease (PD)…
  • 2025 International Congress

    COMT-Inhibitors Clinical Experience In Early Motor Fluctuations. Six Months Analysis Of REONPARK Study

    L. López-Manzanares, M. Cerdán Sánchez, B. Solano Vila, J. García-Caldentey, A. Rodríguez-Sanz, J. Olivares Romero, H. Brigas, D. Martins, J. Blanco Ameijeiras, M. Rodríguez-de Miguel (Madrid, Spain)

    Objective: The REONPARK study aims to evaluate COMT inhibitors (COMTi) effectiveness and tolerability in alleviating motor complications associated with L-dopa treatment in Parkinson’s disease (PD)…
  • 1
  • 2
  • 3
  • …
  • 12
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley